Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHA:605199)
China · Delayed Price · Currency is CNY 5.94
-0.05 (-0.83%)
Sep 10, 2026, 3:00 PM CST
SHA:605199 Revenue
Hainan Huluwa Pharmaceutical Group had revenue of 94.74M CNY in the quarter ending June 30, 2026, a decrease of -44.55%. This brings the company's revenue in the last twelve months to 634.04M, down -38.58% year-over-year. In the year 2025, Hainan Huluwa Pharmaceutical Group had annual revenue of 900.84M, down -36.27%.
Revenue (ttm)
634.04M
Revenue Growth
-38.58%
P/S Ratio
3.78
Revenue / Employee
301.49K
Employees
2,103
Market Cap
2.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 900.84M | -512.71M | -36.27% |
| Dec 31, 2024 | 1.41B | -381.64M | -21.26% |
| Dec 31, 2023 | 1.80B | 280.14M | 18.49% |
| Dec 31, 2022 | 1.52B | 161.25M | 11.91% |
| Dec 31, 2021 | 1.35B | 192.09M | 16.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ShanXi C&Y Pharmaceutical Group Co.,LTD. | 849.67M |
| Zhejiang Shengda Bio-Pharm | 832.86M |
| Enwei Pharmaceutical | 826.13M |
| Jiangxi Synergy Pharmaceutical | 784.40M |
| Chengdu huasun technology group Inc. , LTD. | 486.70M |
| Zhejiang Shapuaisi Pharmaceutical | 423.20M |
| Anhui Huangshan Capsule | 407.10M |
| Guhan Pharmaceutical Group | 329.41M |